Table 3.
Associations of left ventricular mass index quartiles with death in the Chronic Renal Insufficiency Cohort participants without heart failure
| LVMI Q (g/m2.7) | N (Events) | N (Participants) | Rate | HR (95% CI) | ||
|---|---|---|---|---|---|---|
| Model 1 | Model 2 | Model 3 | ||||
| All | ||||||
| Q1 (<41.3) | 46 | 641 | 10.8 | Reference | Reference | Reference |
| Q2 (41.3 to <48.5) | 67 | 643 | 16.0 | 1.21 (0.82 to 1.79) | 1.19 (0.8 to 1.76) | 1.19 (0.79 to 1.78) |
| Q3 (48.5 to <57.5) | 110 | 642 | 27.4 | 1.86 (1.27 to 2.71) | 1.8 (1.23 to 2.64) | 1.7 (1.14 to 2.52) |
| Q4 (≥57.5) | 159 | 641 | 41.8 | 2.22 (1.49 to 3.32) | 2.14 (1.43 to 3.21) | 1.86 (1.22 to 2.85) |
| Linear trend P value | <0.001 | <0.001 | 0.003 | |||
| Men | ||||||
| Q1 (<41.7) | 26 | 345 | 11.4 | Reference | Reference | Reference |
| Q2 (41.7 to <48.8) | 41 | 344 | 18.6 | 1.31 (0.78 to 2.18) | 1.27 (0.76 to 2.12) | 1.25 (0.74 to 2.11) |
| Q3 (48.8 to <57.4) | 70 | 345 | 32.7 | 1.88 (1.15 to 3.08) | 1.83 (1.11 to 2.99) | 1.69 (1.02 to 2.8) |
| Q4 (≥57.4) | 88 | 344 | 43.8 | 2.06 (1.21 to 3.5) | 1.98 (1.17 to 3.36) | 1.7 (0.98 to 2.95) |
| Linear trend P value | 0.003 | <0.01 | 0.07 | |||
| Women | ||||||
| Q1 (<40.8) | 18 | 297 | 9.1 | Reference | Reference | Reference |
| Q2 (40.8 to <47.9) | 25 | 297 | 12.6 | 1.19 (0.63 to 2.24) | 1.2 (0.62 to 2.3) | 1.27 (0.64 to 2.51) |
| Q3 (47.9 to <57.7) | 43 | 298 | 22.9 | 2.23 (1.21 to 4.13) | 2.14 (1.13 to 4.06) | 2.21 (1.12 to 4.36) |
| Q4 (≥57.7) | 71 | 297 | 39.5 | 3.33 (1.74 to 6.36) | 3.2 (1.63 to 6.29) | 3.08 (1.5 to 6.32) |
| Linear trend P value | <0.001 | 0.001 | <0.01 | |||
Model 1: age, race, study site, diabetes, cardiovascular disease, tobacco, alcohol use, log(24-hour proteinuria), eGFR (Chronic Renal Insufficiency Cohort equation), systolic BP, diastolic BP, body mass index, LDL, HDL, aldosterone antagonists, angiotensin–converting enzyme inhibitors, angiotensin receptor blockers, diuretics, β-blockers, phosphate, and hemoglobin. Model 2: model 1 plus log(parathyroid hormone), log(fibroblast growth factor-23), aspirin, and statin. Model 3: model 2 plus log(B–type natriuretic peptide) and log(high–sensitivity troponin T). LVMI, left ventricular mass index; Q, quartile; HR, hazard ratio; 95% CI, 95% confidence interval.